| I-04 Rocio Lledo PK/PD modelling of an anti-FcRn mAb to optimise FIM design - translation from cyno to human Wednesday 10:30-12:00 |
| I-12 Lei Ma Dupilumab dose selection for a phase 3 study in asthma patients: pharmacokinetic/pharmacodynamic (PK/PD) modelling and clinical trial simulation Wednesday 10:30-12:00 |
| I-20 Paolo Mazzei Translational model-based approach to assist the dose-range selection of an antibody-drug conjugate entering Phase I Wednesday 10:30-12:00 |
| I-23 Joske Millecam A new approach in pediatric drug design: the development of a pediatric pig model. Part II: The maturation of hepatic cytochrome P450 enzymes using enzyme activity and proteomics Wednesday 10:30-12:00 |
| I-24 Jonathan Mochel One Health: Translational and Reverse Translational Modeling of Inflammatory Bowel Disease using an advanced Boolean Network Wednesday 10:30-12:00 |
| I-26 Tadakatsu Nakamura Population Pharmacokinetic Analysis of Compound A and Its Metabolite in Healthy Subjects and Patients with Diabetic Nephropathy Wednesday 10:30-12:00 |
| I-27 Srividya Neelakantan Population Pharmacokinetic Analysis of Recombinant Factor VIII Fc Fusion Protein in Subjects with Severe Hemophilia A Across All Ages Wednesday 10:30-12:00 |
| I-33 Boram Ohk Population Pharmacokinetics of Tacrolimus in Healhty Korean Subjects:role of CYP3A5 genotype and metabolite Wednesday 10:30-12:00 |
| I-38 Sang-In Park Population pharmacokinetic analysis of evogliptin in subjects with varying degrees of renal function Wednesday 10:30-12:00 |
| I-40 Christophe Passot In-depth assessment of the influence of anti-drug antibodies on adalimumab pharmacokinetics and concentration-effect relationship in rheumatoid arthritis Wednesday 10:30-12:00 |
| I-48 Chiara Piana A model-based approach to extrapolate drug-drug interactions from rats to humans Wednesday 10:30-12:00 |
| I-53 Manuel Prado-Velasco PBPK versus PK modeling of Tacrolimus drug in patients with renal transplant as knowledge engines for personalized posology software: PhysPK® development and preliminary results Wednesday 10:30-12:00 |
| I-54 Tim Preijers Population pharmacokinetic analysis of perioperative factor IX dosing in hemophilia B Wednesday 10:30-12:00 |
| I-57 Theo Reijmers Population PK Modeling of Dapivirine released from Vaginal Rings Wednesday 10:30-12:00 |
| I-62 Hauke Ruehs Exposure-response analysis of vilaprisan describing uterine fibroid size by population PK/PD modelling Wednesday 10:30-12:00 |
| I-65 Sunae Ryu Population pharmacokinetic model of propranolol and its metabolite reflecting the first-pass effect in patients with hepatic impairment Wednesday 10:30-12:00 |
| I-66 Muhammad Waqas Sadiq A model-based comparison of absorption pharmacokinetics for a selective glucocorticoid receptor modulator administered with different inhalation devices Wednesday 10:30-12:00 |
| II-07 Malte Selch Larsen Using repeated-time-to-event modelling and simulation of spontaneous bleeding events in the F8 KO rat model for informed decision making of study design Wednesday 15:10-16:30 |
| II-09 Jennifer Sheng Joint modeling of time-varying exposure data and progression-free survival in elotuzumab-treated patients with relapsed/refractory multiple myeloma Wednesday 15:10-16:30 |
| II-10 Satoshi Shoji Slow drug-target complex kinetics and first dose overestimation of free target suppression in target-mediated drug disposition (TMDD) approximation models: An evaluation for tanezumab a NGF antibody for treatment of pain Wednesday 15:10-16:30 |
| II-13 Sarah Siederer Model Based Extrapolation Approach Driving a Streamlined Clinical Development Plan for Inhaled Oxytocin Wednesday 15:10-16:30 |
| II-17 Sabine Stuebler Towards a systems biology model for inflammatory bowel disease Wednesday 15:10-16:30 |
| II-20 Monika Sundqvist Preclinical pharmacokinetic-pharmacodynamic modelling to guide first-time-in-human studies with the anti-miR-103/107, RG-125 (AZD4076) Wednesday 15:10-16:30 |
| II-28 Valentina Topic Vucenovic Nonlinear mixed effects modelling approach for investigation of 131I kinetics in patients with benign thyroid disease Wednesday 15:10-16:30 |
| II-41 Tamara van Donge Impact of rise in anti-drug antibodies on the pharmacokinetics of the monoclonal antibody adalimumab Wednesday 15:10-16:30 |
| II-44 Erno van Schaick CHF5993 a triple combination therapy for COPD patients: population PK modelling of formoterol following pMDI inhalation Wednesday 15:10-16:30 |
| II-45 Rob van Wijk A parent-metabolite pharmacokinetic model of paracetamol in zebrafish Wednesday 15:10-16:30 |
| II-61 Rujia Xie Population pharmacokinetics of PF-04447943 in healthy volunteers (HV), adult patients with Alzheimer's disease (AD) and patients with Sickle Cell Disease (SCD) Wednesday 15:10-16:30 |
| II-63 Christine Xu Population pharmacokinetics of sarilumab in patients with rheumatoid arthritis Wednesday 15:10-16:30 |
| II-64 Dong-Seok Yim Discrepancy between in vitro potency and in vivo efficacy in human - Implications in PK-PD modeling Wednesday 15:10-16:30 |
| II-65 Anyue Yin Population pharmacokinetics analysis of olanzapine for Chinese psychotic patients based on clinical therapeutic drug monitoring data with assistance of meta-analysis Wednesday 15:10-16:30 |
| II-68 Chiara Zecchin Quantitative modelling to assess target engagement and pharmacology in early clinical development of an anti-OSM humanised mAb Wednesday 15:10-16:30 |
| II-69 Meng Zhaoling Exposure/Response modeling for sarilumab dose regimens benefit/risk assessment Wednesday 15:10-16:30 |
| III-06 Cecilia Fosser Model based predictions of the PTG-100 pharmacodynamic responses in ulcerative colitis patients Thursday 09:50-11:20 |
| III-16 Anais Glatard Varenicline exposure is associated with abstinence from smoking in a cohort of smokers from the general population Thursday 09:50-11:20 |
| III-22 Ana-Marija Grisic Towards understanding the loss of response to infliximab in patients with inflammatory bowel disease: A population PK modelling approach Thursday 09:50-11:20 |
| III-26 Serge Guzy Population Pharmacokinetic of L-DOPA and its main metabolites: Use of the Phoenix based QRPEM algorithm Thursday 09:50-11:20 |
| III-27 Bengt Hamrén Pharmacokinetic and exposure-response analyses supporting ticagrelor dosing recommendation in patients with prior myocardial infarction (PEGASUS-TIMI 54) Thursday 09:50-11:20 |
| III-31 Lee Heechan A population parmacokinetic analysis of fimasartan, a novel angiotensin-receptor antagonist, in healthy subjects and patients with hypertension Thursday 09:50-11:20 |
| III-38 Candice Jamois Quantification of Anti-Drug-Antibodies (ADA) Impact on Drug Exposure Using a Population PK modeling Approach Thursday 09:50-11:20 |
| III-43 Koen Jolling CHF5993 a triple combination therapy for COPD patients: population pharmacokinetic modelling of beclometasone-17-monopropionate (B17MP) following pMDI inhalation. Thursday 09:50-11:20 |
| III-49 Yu Kyong Kim Population Pharmacokinetic Model Development for Long-Acting Intramuscular Injection of Drug X in Healthy Subjects Thursday 09:50-11:20 |
| III-64 Jacob Leander Pharmacodynamic modeling of uric acid turnover and the effect of Verinurad (RDEA3170), a novel selective uric acid reabsorption inhibitor for the treatment of gout and asymptomatic hyperuricemia Thursday 09:50-11:20 |
| III-68 Sarah Lezzar Population pharmacokinetics and pharmacodynamics analysis of hydroxyurea, in adult patients with sickle cell anemia (SCA), and evaluation of disease markers Thursday 09:50-11:20 |
| IV-11 Suruchi Bakshi Systems pharmacology modelling of alternative pathway of complement activation Thursday 14:45-16:15 |
| IV-13 Violeta Balbas-Martinez Validation of a Network Systems Pharmacology model for Inflammatory Bowel Thursday 14:45-16:15 |
| IV-16 Carla Bastida Fernández Population pharmacokinetic model for intravenous tocilizumab in rheumatoid arthritis Thursday 14:45-16:15 |
| IV-18 Sophie Berends A Target-Mediated Drug Disposition model for infliximab in patients with Ulcerative Colitis Thursday 14:45-16:15 |
| IV-31 Sophie Callies Increase in glucose as pharmacodynamic biomarker following administration of the PI3K/mTOR inhibitor LY3023414: quantitative description using modelling. Thursday 14:45-16:15 |
| IV-34 Massimo Cella CHF5993 a triple combination therapy for COPD patients: population PK modelling of glycopyrronium bromide (GB) following pMDI inhalation. Thursday 14:45-16:15 |
| IV-43 Maxwell Chirehwa A semi-physiological model for moxifloxacin pharmacokinetics which includes the effect of co-administered drugs and genetic polymorphisms Thursday 14:45-16:15 |
| IV-47 Pieter Colin Dexmedetomidine pharmacodynamics in healthy volunteers: Striking a balance between the hypnotic and sedative properties and the haemodynamic side effects. Thursday 14:45-16:15 |
| IV-48 Camille Couffignal Population pharmacokinetic modelling of sustained-release lithium in the serum, erythrocytes and urine of patients with bipolar disorder. Thursday 14:45-16:15 |
| IV-56 Neel Deferm Modeling of telmisartan disposition in sandwich-cultured rat hepatocytes. Does cryopreservation change disposition kinetics? Thursday 14:45-16:15 |
| IV-58 Chenhui Deng Tofacitinib exposure-response modeling of partial Mayo score in ulcerative colitis patients in phase 3 induction studies Thursday 14:45-16:15 |
| IV-59 Menshykau Denis Computational Modelling of Personalized Hemodynamic Response to Valve Replacement Surgery in Heart Failure Patients Thursday 14:45-16:15 |
| IV-62 Cheikh Diack A model-based meta-marker to characterize the response to ranibizumab in wet AMD patients Thursday 14:45-16:15 |
